Dementia with Lewy bodies
Keywords:dementia with Lewy bodies, Lewy body dementia, Alpha-synuclein, dementia, Alzheimer’s disease, Parkinson’s disease with dementia
Dementia with Lewy bodies (DLB) is a common neurodegenerative condition. DLB is the second most common cause of neurodegenerative dementia after Alzheimer’s disease. DLB patients present with a wide range of cognitive impairment, neuropsychiatric symptoms, sleep behavior disorder, motor and autonomic dysfunction. The clinical presentations vary between patients and can change over time within an individual. DLB is characterized by the accumulation of aggregated alpha-synuclein protein in Lewy bodies and Lewy neurites, similar to Parkinson’s disease. The result of treatments is promising in one symptom but worsen another, which makes disease management difficult. There are currently no US FDA-approved medications specifically for the treatment of DLB, though many of them that are approved for Alzheimer’s disease are widely used in the treatment of DLB with varying degrees of success. This article presents the basic concepts, symptoms, pathology and pathogenesis and the latest updated new criteria information of DLB based on current understanding to help teams of physicians and caregivers inform those in need about the disease and provide adequate support for DLB patients
2. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045-7.
3. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839-40.
4. Holdorff B. Friedrich Heinrich Lewy (1885-1950) and his work. J Hist Neurosci. 2002;11:19-28.
5. McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94:743-55.
6. U.S. Department of Health and Human Services. Lewy body dementia: information for patients, families, and professionals (Revised June 2018). North Carolina: Lulu.com; 2019. p. 44.
7. Savica R, Boeve BF, Mielke MM. When Do -synucleinopathies start? An epidemiological timeline: a review. JAMA Neurol. 2018;75:503-9.
8. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord Off J Mov Disord Soc. 2007;22:1689-707; quiz 1837.
9. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89:88-100.
10. Killen A, Flynn D, De Brún A, O’Brien N, O’Brien J, Thomas AJ, et al. Support and information needs following a diagnosis of dementia with Lewy bodies. Int Psychogeriatr. 2016;28:495-501.
11. Zweig YR, Galvin JE. Lewy body dementia: the impact on patients and caregivers. Alzheimers Res Ther. 2014;6:21.
12. Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet Lond Engl. 2015; 386:1683-97.
13. Mueller C, Ballard C, Corbett A, Aarsland D. The prognosis of dementia with Lewy bodies. Lancet Neurol. 2017;16:390-8.
14. Weiner MF, Lipton AM, editors. The American Psychiatric Publishing Textbook of Alzheimer Disease and Other Dementias [Internet]. American Psychiatric Association Publishing;2009 [cited 2021 Mar 22]. Available from: http://psychiatryonline.org/doi/book/10.1176/appi.books.9781585628940
15. Outeiro TF, Koss DJ, Erskine D, Walker L, Kurzawa-Akanbi M, Burn D, et al. Dementia with Lewy bodies: an update and outlook. Mol Neurodegener. 2019;14:5.
16. Coughlin DG, Hurtig HI, Irwin DJ. Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases. Mov Disord Off J Mov Disord Soc. 2020;35:5-19.
17. Berthoud HR, Neuhuber WL. Functional and chemical anatomy of the afferent vagal system. Auton Neurosci Basic Clin. 2000;85:1-17.
18. Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology. 2000;54:407-11.
19. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113-24.
20. Mrak RE, Griffin WST. Dementia with Lewy bodies: Definition, diagnosis, and pathogenic relationship to Alzheimer’s disease. Neuropsychiatr Dis Treat. 2007;3:619-25.
21. Vossius C, Rongve A, Testad I, Wimo A, Aarsland D. The use and costs of formal care in newly diagnosed dementia: a three-year prospective follow-up study. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2014;22:381-8.
22. Lippa CF, Smith TW, Swearer JM. Alzheimer’s disease and Lewy body disease: a comparative clinicopathological study. Ann Neurol. 1994; 35:81-8.
23. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863-72.
24. Mckeith IG, Fairbairn AF, Perry RH, Thompson P. The Clinical Diagnosis and Misdiagnosis of Senile Dementia of Lewy Body Type (SDLT). Br J Psychiatry. 1994;165:324-32.
25. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain J Neurol. 2002;125:391-403.
26. McKeith IG. Spectrum of Parkinson’s disease, Parkinson’s dementia, and Lewy body dementia. Neurol Clin. 2000;18:865-902.
27. Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer’s disease and Parkinson’s disease comparison groups. Neurology. 1996;47:1148-52.
28. Ballard C, Aarsland D, Francis P, Corbett A. Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology, clinical features, and pharmacological management. Drugs Aging. 2013; 30:603-11.
29. Taylor J-P, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19:157-69.
30. Ballard CG, Aarsland D, McKeith I, O’Brien J, Gray A, Cormack F, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology. 2002;59:1714-20.
31. Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O’Brien JT, et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry J Ment Sci. 2000;177:252-6.
32. Yamada M, Komatsu J, Nakamura K, Sakai K, Samuraki-Yokohama M, Nakajima K, et al. Diagnostic Criteria for Dementia with Lewy Bodies: Updates and Future Directions. J Mov Disord. 2020;13:1-10.
33. Aarsland D, Perry R, Larsen JP, McKeith IG, O’Brien JT, Perry EK, et al. Neuroleptic sensitivity in Parkinson’s disease and parkinsonian dementias. J Clin Psychiatry. 2005;66:633-7.
34. Dantuma NP, Salomons FA. Ubiquitin versus misfolding: The minimal requirements for inclusion body formation. J Cell Biol. 2016;213:147-9.
35. Chung EJ, Kim SJ. (123)I-Metaiodobenzylguanidine myocardial scintigraphy in Lewy body-related disorders: a literature review. J Mov Disord. 2015;8:55-66.
36. Dijkstra F, Van den Bossche K, de Bruyn B, Reyn N, Viaene M, De Volder I, et al. REM sleep without atonia and the relation with Lewy body disease. Parkinsonism Relat Disord. 2019;67:90-8.
37. Connors MH, Quinto L, McKeith I, Brodaty H, Allan L, Bamford C, et al. Non-pharmacological interventions for Lewy body dementia: a systematic review. Psychol Med. 2018;48:1749-58.
38. Dementia with Lewy bodies - Treatment [Internet]. nhs.uk. 2017 [cited 2021 Mar 22]. Available from: https://www.nhs.uk/conditions/dementia-with-lewy-bodies/treatment/